Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amjodaron - koncentrat za raztopino za injiciranje/infundiranje - amjodaron 46,9 mg / 1 ampula - amjodaron

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - amjodaron - koncentrat za raztopino za injiciranje/infundiranje - amjodaron 141,9 mg / 3 ml - amjodaron

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amjodaron - raztopina za infundiranje - amjodaron 18,93 mg / 1 ml - amjodaron

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

medias international d.o.o. - bakrov(ii) klorid dihidrat; cinkov klorid; kalijev jodid; kromov(iii) klorid heksahidrat; manganov(ii) klorid tetrahidrat; natrijev fluorid; natrijev molibdat dihidrat; natrijev selenit, brezvodni; železov(iii) klorid heksahidrat - koncentrat za raztopino za infundiranje - bakrov(ii) klorid dihidrat 102,3 µg / 1 ml  cinkov klorid1050 µg / 1 ml  kalijev jodid16,6 µg / 1 ml  kromov(iii) klorid heksahidrat5,33 µg / 1 ml  manganov(ii) klorid tetrahidrat19,8 µg / 1 ml  natrijev fluorid210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni17,3 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; cinkov klorid 1050 µg / 1 ml  kalijev jodid16,6 µg / 1 ml  kromov(iii) klorid heksahidrat5,33 µg / 1 ml  manganov(ii) klorid tetrahidrat19,8 µg / 1 ml  natrijev fluorid210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni17,3 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; kalijev jodid 16,6 µg / 1 ml  kromov(iii) klorid heksahidrat5,33 µg / 1 ml  manganov(ii) klorid tetrahidrat19,8 µg / 1 ml  natrijev fluorid210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni17,3 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; kromov(iii) klorid heksahidrat 5,33 µg / 1 ml  manganov(ii) klorid tetrahidrat19,8 µg / 1 ml  natrijev fluorid210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni17,3 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; manganov(ii) klorid tetrahidrat 19,8 µg / 1 ml  natrijev fluorid210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni17,3 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; natrijev fluorid 210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni17,3 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; natrijev molibdat dihidrat 4,85 µg / 1 ml  natrijev selenit, brezvodni17,3 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; natrijev selenit, brezvodni; železov(iii) klorid heksahidrat 540 µg / 1 ml - kombinacije elektrolitov z drugimi učinkovinami

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

medias international d.o.o. - bakrov(ii) klorid dihidrat; cinkov klorid; kalijev jodid; manganov(ii) klorid tetrahidrat; natrijev fluorid; natrijev selenit, brezvodni - koncentrat za raztopino za infundiranje - bakrov(ii) klorid dihidrat 53,7 µg / 1 ml  cinkov klorid521 µg / 1 ml  kalijev jodid1,31 µg / 1 ml  manganov(ii) klorid tetrahidrat3,6 µg / 1 ml  natrijev fluorid126 µg / 1 ml  natrijev selenit, brezvodni4,38 µg / 1 ml; cinkov klorid 521 µg / 1 ml  kalijev jodid1,31 µg / 1 ml  manganov(ii) klorid tetrahidrat3,6 µg / 1 ml  natrijev fluorid126 µg / 1 ml  natrijev selenit, brezvodni4,38 µg / 1 ml; kalijev jodid 1,31 µg / 1 ml  manganov(ii) klorid tetrahidrat3,6 µg / 1 ml  natrijev fluorid126 µg / 1 ml  natrijev selenit, brezvodni4,38 µg / 1 ml; manganov(ii) klorid tetrahidrat 3,6 µg / 1 ml  natrijev fluorid126 µg / 1 ml  natrijev selenit, brezvodni4,38 µg / 1 ml; natrijev fluorid 126 µg / 1 ml  natrijev selenit, brezvodni4,38 µg / 1 ml; natrijev selenit, brezvodni 4,38 µg / 1 ml - kombinacije elektrolitov z drugimi učinkovinami

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - jod - dermalna raztopina/koncentrat za dermalno raztopino - jod 10 mg / 1 ml - povidon-jod

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

menarini international o.l.s.a. - deksketoprofen - raztopina za injiciranje/infundiranje - deksketoprofen 25 mg / 1 ml - deksketoprofen

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakonazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimikotiki za sistemsko uporabo - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 in 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 in 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je opredeljena kot napredovanje okužbe ali neuspeh za izboljšanje po najmanj 7 dni pred terapevtskih odmerkih učinkovito protiglivično zdravljenje. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 in 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 in 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 in 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je opredeljena kot napredovanje okužbe ali neuspeh za izboljšanje po najmanj 7 dni pred terapevtskih odmerkih učinkovito protiglivično zdravljenje. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 in 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 in 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je opredeljena kot napredovanje okužbe ali neuspeh za izboljšanje po najmanj 7 dni pred terapevtskih odmerkih učinkovito protiglivično zdravljenje. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invazivne aspergillosis pri bolnikih z boleznijo, ki je neodzivna, da amphotericin b ali itraconazole ali pri bolnikih, ki ne prenašajo teh zdravil;- fusariosis pri bolnikih z boleznijo, ki je neodzivna, da amphotericin b ali pri bolnikih, ki so nestrpne amphotericin b;- chromoblastomycosis in mycetoma pri bolnikih z boleznijo, ki je neodzivna, da itraconazole ali pri bolnikih, ki so nestrpne itraconazole;- coccidioidomycosis pri bolnikih z boleznijo, ki je neodzivna, da amphotericin b, itraconazole ali fluconazole ali pri bolnikih, ki ne prenašajo teh zdravil;- Žrela kandidoza: kot prvo linijo zdravljenja pri bolnikih, ki imajo hude bolezni ali so immunocompromised, v kateri je odziv na aktualne terapija je pričakovati, da bo slaba. refractoriness je opredeljena kot napredovanje okužbe ali neuspeh za izboljšanje po najmanj 7 dni pred terapevtskih odmerkih učinkovito protiglivično zdravljenje. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

medias international d.o.o. - bakrov(ii) klorid dihidrat; cinkov klorid; kalijev jodid; kromov(iii) klorid heksahidrat; manganov(ii) klorid tetrahidrat; natrijev fluorid; natrijev molibdat dihidrat; natrijev selenit, brezvodni; železov(iii) klorid heksahidrat - koncentrat za raztopino za infundiranje - bakrov(ii) klorid dihidrat 340 µg / 1 ml  cinkov klorid1360 µg / 1 ml  kalijev jodid16,6 µg / 1 ml  kromov(iii) klorid heksahidrat5,33 µg / 1 ml  manganov(ii) klorid tetrahidrat99 µg / 1 ml  natrijev fluorid210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni6,9 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; cinkov klorid 1360 µg / 1 ml  kalijev jodid16,6 µg / 1 ml  kromov(iii) klorid heksahidrat5,33 µg / 1 ml  manganov(ii) klorid tetrahidrat99 µg / 1 ml  natrijev fluorid210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni6,9 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; kalijev jodid 16,6 µg / 1 ml  kromov(iii) klorid heksahidrat5,33 µg / 1 ml  manganov(ii) klorid tetrahidrat99 µg / 1 ml  natrijev fluorid210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni6,9 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; kromov(iii) klorid heksahidrat 5,33 µg / 1 ml  manganov(ii) klorid tetrahidrat99 µg / 1 ml  natrijev fluorid210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni6,9 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; manganov(ii) klorid tetrahidrat 99 µg / 1 ml  natrijev fluorid210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni6,9 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; natrijev fluorid 210 µg / 1 ml  natrijev molibdat dihidrat4,85 µg / 1 ml  natrijev selenit, brezvodni6,9 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; natrijev molibdat dihidrat 4,85 µg / 1 ml  natrijev selenit, brezvodni6,9 µg / 1 ml  železov(iii) klorid heksahidrat540 µg / 1 ml; natrijev selenit, brezvodni; železov(iii) klorid heksahidrat 540 µg / 1 ml - kombinacije elektrolitov z drugimi učinkovinami

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

g.l. pharma gmbh - jod - tableta - jod 50 mg / 1 tableta - kalijev jodid